Abstract
Folic acid, transferrin and integrin alpha v beta 3 (αvβ3) receptors are overexpressed in various cancer cell lines. Ligands having high affinity for these receptors are often conjugated to nanocarriers to facilitate the tumor localization of therapeutic agents. In this review the use of these ligands for targeted delivery using liposomes, dendrimers and (N-(2- hydroxypropyl) methacrylamide) (HPMA) copolymers is discussed. Emphasis is placed on discussing drug delivery systems that have been optimized for in-vitro binding as well as in-vivo pharmacokinetics. Our aim is to understand the various factors influencing the targeting ability of nanocarriers.
Keywords: Polymeric drug delivery, liposomes, dendrimer, HPMA, folic acid, transferrin, integrin alpha v beta, tumor targeting, Polymers, micelles
Current Drug Discovery Technologies
Title: Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Volume: 8 Issue: 3
Author(s): Rohit Kolhatkar, Asawari Lote and Hiren Khambhati
Affiliation:
Keywords: Polymeric drug delivery, liposomes, dendrimer, HPMA, folic acid, transferrin, integrin alpha v beta, tumor targeting, Polymers, micelles
Abstract: Folic acid, transferrin and integrin alpha v beta 3 (αvβ3) receptors are overexpressed in various cancer cell lines. Ligands having high affinity for these receptors are often conjugated to nanocarriers to facilitate the tumor localization of therapeutic agents. In this review the use of these ligands for targeted delivery using liposomes, dendrimers and (N-(2- hydroxypropyl) methacrylamide) (HPMA) copolymers is discussed. Emphasis is placed on discussing drug delivery systems that have been optimized for in-vitro binding as well as in-vivo pharmacokinetics. Our aim is to understand the various factors influencing the targeting ability of nanocarriers.
Export Options
About this article
Cite this article as:
Kolhatkar Rohit, Lote Asawari and Khambhati Hiren, Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796799044
DOI https://dx.doi.org/10.2174/157016311796799044 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry The Interest of Folic Acid in Targeted Photodynamic Therapy
Current Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System
Current Pharmaceutical Biotechnology Dendrimers in Oral Drug Delivery Application: Current Explorations, Toxicity Issues and Strategies for Improvement
Current Pharmaceutical Design Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Personalized Peptide Vaccine for Treatment of Advanced Cancer
Current Medicinal Chemistry Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Role of Mismatch Repair and MGMT in Response to Anticancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry